Zacks: Brokerages Set $8.00 Price Target for Evogene Ltd. (EVGN)

Evogene Ltd. (NASDAQ:EVGN) has been assigned a consensus broker rating score of 3.00 (Hold) from the one brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating.

Analysts have set a 1 year consensus price objective of $8.00 for the company and are forecasting that the company will post ($0.18) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Evogene an industry rank of 179 out of 265 based on the ratings given to its competitors.

An institutional investor recently raised its position in Evogene stock. Vanguard Group Inc. lifted its position in shares of Evogene Ltd. (NASDAQ:EVGN) by 4.2% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 436,225 shares of the biotechnology company’s stock after purchasing an additional 17,391 shares during the quarter. Vanguard Group Inc. owned about 1.70% of Evogene worth $2,443,000 as of its most recent filing with the SEC. 30.94% of the stock is owned by hedge funds and other institutional investors.

Evogene (NASDAQ:EVGN) traded down $0.06 on Monday, reaching $3.83. The company’s stock had a trading volume of 2,000 shares, compared to its average volume of 18,225. The stock has a market cap of $98.62, a PE ratio of -4.61 and a beta of 1.36. Evogene has a 52 week low of $2.66 and a 52 week high of $5.84.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings results on Wednesday, November 22nd. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Evogene had a negative net margin of 555.45% and a negative return on equity of 26.17%. equities analysts predict that Evogene will post -0.74 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/22/zacks-brokerages-set-8-00-price-target-for-evogene-ltd-evgn.html.

About Evogene

Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd.

Get a free copy of the Zacks research report on Evogene (EVGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply